America’s Comeback as the Global Leader in Medical Research

RFK Jr. argues the U.S. must reclaim its lead in clinical trials and medical innovation, warning that China is ahead in early-stage testing and that Chinese firms accounted for nearly half of global pharma licensing deals in 2025. He outlines Trump-era reforms across FDA, NIH, ONC and ARPA-H to accelerate development while preserving safety, and calls for broad collaboration among researchers, health systems, tech companies and regulators to restore America’s competitive edge and patient access to new therapies.